ACHV - アチ―ブ・ライフ・サイエンス (Achieve Life Sciences Inc. ) アチ―ブ・ライフ・サイエンス

 ACHVのチャート


 ACHVの企業情報

symbol ACHV
会社名 Achieve Life Science Inc (アチ―ブ・ライフ・サイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アチーブ・ライフ・サイエンス(Achieve Life Sciences Inc.)(旧名:OncoGenex Pharmaceuticals Inc)は癌患者の治療抵抗性に対応する治療法の開発・商業化に従事する臨床段階のバイオ医薬品会社である。同社はカナダおよび米国に事業を展開するがん治療の開発・商品化に従事する。同社は「Custirsen」、「Apatorsen」及び「OGX-225」の3種類の薬品候補を保有する。同社は腫瘍細胞の適応防御を無効にするために、これらの特定のタンパク質を標的にする。それによって、各種のがん治療法による攻撃を受けやすい腫瘍細胞をレンダリングする。「Custirsen」と「Apatorsen」は臨床段階の製品候補である。「Custirsen」は2つの第III相試験で評価される。「Apatorsen」は熱ショックタンパク質27(Hsp27)の産生を阻害するように設計された製品候補である。  アチ―ブ・ライフ・サイエンスは米国のバイオ医薬品メ―カ―。がん治療薬の開発と商業化を手掛ける。製品候補にはcustirsen、apatorsen、およびOGX-225があり、前立腺がん治療のCustirsen、未治療膵癌治療のapatorsenは臨床試験段階にある。本社所在地はワシントン州。   Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
本社所在地 1001 W. Broadway Suite 400 Vancouver British Columbia 98011 CAN
代表者氏名 Richard Stewart リチャード・スチュワート
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 425-686-1500
設立年月日 33512
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 13人
url www.oncogenex.com
nasdaq_url https://www.nasdaq.com/symbol/achv
adr_tso
EBITDA EBITDA(百万ドル) -11.66100
終値(lastsale) 2.53
時価総額(marketcap) 11514042.65
時価総額 時価総額(百万ドル) 14.76807
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -0.48293
当期純利益 当期純利益(百万ドル) -16.02200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Achieve Life Sciences Inc revenues was not reported. Net loss increased from $371K to $5.8M. Higher net loss reflects General_Administrative increase from $352K to $3.3M (expense) Research_Development increase from $123K to $2.1M (expense) General and administrative increase from $0K to $258K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.77 to -$4.25.

 ACHVのテクニカル分析


 ACHVのニュース

   Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option  2019/12/19 21:05:00 PR Newswire
SEATTLE and VANCOUVER, British Columbia, Dec. 19, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today…
   The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data  2019/12/18 12:23:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Medtronic PLC (NYSE: MDT )(announced acquisition of Klue, a software company focused on behavior tracking) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nantkwest Inc (NASDAQ: NK ) Novo Nordisk A/S (NYSE: NVO ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) NuVasive, Inc. (NASDAQ: NUVA ) Ovid Therapeutics Inc (NASDAQ: OVID ) Prevail Therapeutics Inc (NASDAQ: PRVL )( announced Orphan Drug Designation for its dementia asset) Principia Biopharma Inc (NASDAQ: PRNB ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) ResMed Inc. (NYSE: RMD ) Soligenix, Inc.
   Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering  2019/12/17 18:06:00 PR Newswire
SEATTLE and VANCOUVER, British Columbia, Dec. 17, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today…
   The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer  2019/12/13 13:10:02 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.
   The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint  2019/12/11 12:21:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL )(agreed to be bought by Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Bristol-Myers Squibb Co (NYSE: BMY )(reacted to ASH presentation) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GlaxoSmithKline plc (NYSE: GSK ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) The Medicines Company (NASDAQ: MDCO ) Merck & Co.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アチ―ブ・ライフ・サイエンス ACHV Achieve Life Sciences Inc. )

 twitter  (公式ツイッターやCEOツイッターなど)